Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Natera, Inc. (NASDAQ:NTRA), a $25.9 billion market cap company whose stock has surged 53% over the past year and is trading near its 52-week high of $187.34, reported that Executive Chairman Matthew Rabinowitz sold 10,000 shares of common stock on October 20, 2025, at a price of $190.0, for a total transaction value of $1.9 million.
Following the transaction, Rabinowitz directly owns 2,320,852 shares of Natera, Inc. common stock. Additionally, Rabinowitz indirectly owns 5,000 shares through a spouse. The sale was executed under a Rule 10b5-1 trading plan adopted on June 13, 2025. According to InvestingPro, Natera maintains a GREAT financial health score, with 12+ additional exclusive insights available to subscribers.
In other recent news, Natera has been active with several key developments. The company announced that it has enrolled over 1,600 patients in its EXPAND clinical trial for fetal testing, aimed at evaluating its Fetal Focus noninvasive prenatal test. Additionally, Natera’s Signatera test has shown promising results in the largest-ever study of circulating tumor DNA (ctDNA) for testicular cancer, outperforming standard tumor markers in predicting patient outcomes. This study was published in the Journal of Clinical Oncology - Precision Oncology. Furthermore, the Signatera test has demonstrated strong results in monitoring uterine cancer, with findings published in the same journal. Analysts at Canaccord Genuity maintained a Buy rating and a $200 price target on Natera, emphasizing the company’s leadership in molecular residual disease testing. Meanwhile, Wells Fargo resumed coverage of Natera with an Equal Weight rating and set a price target of $175, highlighting the company’s robust position in the cell-free DNA testing market. Natera is also set to present 14 abstracts at the European Society for Medical Oncology Congress, reinforcing its focus on early cancer detection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.